Meeting
2012 ASCO Annual Meeting
Bevacizumab, etoposide, and cisplatin (BEEP) in brain metastases of breast cancer progressing from radiotherapy: Results of the first stage of a multicenter phase II study.
Authors
Yen-Shen Lu
Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
Yen-Shen Lu , Wei-Wu Chen , Ching-Hung Lin , Ling-Ming Tseng , Dah-Cherng Yeh , Pei-Fang Wu , Bang-Bin Chen , Ta-Chung Chao , Yi-Fang Tsai , Shu-Min Huang , Tiffany Ting-Fang Shih , Ann-Lii Cheng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Cytotoxic Chemotherapy
Clinical Trial Registration Number
NCT01281696
Citation
J Clin Oncol 30, 2012 (suppl; abstr 1079)
DOI
10.1200/jco.2012.30.15_suppl.1079
Abstract #
1079
Poster Bd #
24F
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Induction bevacizumab, etoposide and cisplatin followed by whole brain radiotherapy (WBRT) versus WBRT alone in breast cancer with untreated brain metastases: Results of a randomized phase II A-PLUS trial.
First Author: Yen-Shen Lu
Poster
2014 ASCO Annual Meeting
Phase 2 trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) for refractory germ-cell tumors (GCT).
First Author: Yago Nieto
Poster
2012 ASCO Annual Meeting
Phase II trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) for refractory germ-cell tumors (GCT).
First Author: Yago Nieto
Poster
2023 ASCO Annual Meeting
The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.
First Author: Jianqing Zhu